{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
methyl salicylate
to a specific field?
Status:
Investigational
Source:
NCT03414034: Phase 2 Interventional Completed Metastatic Castration-Resistant Prostate Cancer
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
NMS-P937 is a selective PLK1 inhibitor. It was developed by Nerviano Medical Sciences and tested in phase I clinical trials.
Status:
Investigational
Source:
NCT04390295: Phase 3 Interventional Unknown status Type 2 Diabetes Mellitus
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Henagliflozin (also known as SHR3824) was developed by Jiangsu HengRui Medicine as a sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. This drug successfully passed phase I clinical trials, however, information about further development is not available.
Class (Stereo):
CHEMICAL (ACHIRAL)
Vintiamol was developed as a new form of vitamin B1. Information about the current use of this agent is not available.
Status:
Investigational
Source:
NCT00923520: Phase 1 Interventional Completed Renal Cell Carcinoma
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Class (Stereo):
CHEMICAL (ABSOLUTE)
Iosarcol (also known as Melitrast) is an iodinated nonionic monomeric contrast medium patented by Dr. Franz Koehler and Chemie KG for radiographic imaging.
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Mindodilol (also known as BM 12,434) was investigated as a beta-adrenoceptor-blocking agent. This drug was potentially useful for the treatment of both coronary heart disease and of arterial hypertension. However, information about the further development of this drug is not available.
Status:
Investigational
Source:
NCT01740986: Phase 2 Interventional Completed Mild to Moderate Bronchial Asthma
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Masilukast (ZD 3523) is an antagonist of leukotriene D4 (LTD4). It opposes LTD4-induced bronchoconstriction. It was being developed for the treatment of asthma.
Class (Stereo):
CHEMICAL (RACEMIC)
FLUDOREX is an antiemetic and anorexic agent.
Status:
Investigational
Source:
NCT03833362: Phase 3 Interventional Completed Hepatitis C
(2014)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Narlaprevir (formerly SCH 900518), a NS3 protease inhibitor is being developed by R-Pharm for the treatment of a chronic hepatitis C (genotype 1). Narlaprevir is a potent inhibitor of hepatitis C virus (HCV) NS3 protease with a Ki of 7 ± 1 nM and a 90% inhibitory concentration (IC90) of ∼28 ng/ml for HCV genotype 1 replicon in vitro. Narlaprevir successfully passed extensive pre-clinical and clinical trials in Schering-Plough Research Institute (USA) and in a variety of clinical centers of Europe, USA and Russia. Based on clinical findings R-Pharm obtained a registration certificate for Arlansa (Narlaprevir) ЛП-003622 dd 12.05.2016 issued by Ministry of Healthcare of the Russian Federation.
Status:
Investigational
Source:
NCT00365105: Phase 3 Interventional Completed Breast Cancer
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
